A detailed history of Alliancebernstein L.P. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 29,240 shares of JANX stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,240
Previous 23,550 24.16%
Holding current value
$1.59 Million
Previous $886,000 38.15%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $199,832 - $368,598
5,690 Added 24.16%
29,240 $1.22 Million
Q1 2024

May 14, 2024

BUY
$7.93 - $49.75 $49,007 - $307,455
6,180 Added 35.58%
23,550 $886,000
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $2,983 - $5,967
510 Added 3.02%
17,370 $186,000
Q3 2023

Nov 14, 2023

BUY
$9.56 - $14.0 $17,494 - $25,620
1,830 Added 12.18%
16,860 $169,000
Q2 2023

Aug 15, 2023

BUY
$11.08 - $15.92 $166,532 - $239,277
15,030 New
15,030 $178,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.